Al-Nahrain Journal of Science
ANJS, Vol.28(2), June, 2025, pp. 73-91

Herb Composites in Medicinal Applications: Synergistic Formulations and Historical Foundations

Khalid Zainulabdeen[1,*], Reem W. Younus[2], Shams Ismael[3], Asmaa Hadi Mohammed[4], Muna Bufaroosha[5], Emad Al-Sarraj[1]

[1]Department of Chemistry, College of Sciences, University of Al-Nahrain, Baghdad, Iraq
[2]Department of Biotechnology, College of Science/ University of Baghdad, Baghdad, Iraq
[3]Department of Medical Physics, College of Sciences, Al-Nahrain University, Baghdad, Iraq
[4]Department of Physics, College of Sciences, University of Al-Nahrain, Baghdad, Iraq
[5]Department of Chemistry, College of Science, United Arab Emirates University, Al-Ain, United Arab of Emirates

Article's Information

Received: 11.03.2025
Accepted: 03.04.2025
Published: 15.06.2025

Keywords:
Herb Composites, Synergistic Formulations,
Traditional Chinese Medicine,
Clinical Validation,
Phytochemical Profiles

Abstract

Herbal composites, or polyherbal formulations, have been used in traditional medicine practices such as Traditional Chinese Medicine (TCM) and Ayurveda, leveraging the synergistic interactions among multiple plant species to enhance therapeutic outcomes. This review aims to summarize the current state of knowledge on herbal composites, exploring their mechanisms of action, potential benefits, and challenges associated with their development and clinical validation. The results highlight the synergistic interactions among herbs, including pharmacokinetic interactions where one herb influences the absorption or metabolism of another, and pharmacodynamic interactions where compounds target different biological pathways, leading to improved efficacy and bioavailability, as well as enhanced safety profiles. In conclusion, despite their potential, herbal composites face significant challenges, including the standardization of phytochemical profiles and concerns regarding herb-drug interactions. Therefore, it is recommended that rigorous clinical validation through larger, multi-center randomized controlled trials is essential to confirm the safety and efficacy of herbal composites, and that standardization of phytochemical profiles and careful evaluation of herb-drug interactions are also crucial to enhance the reliability of these formulations, ultimately allowing herbal composites to become a more integral part of modern medicine, offering new treatment options for patients.

http://doi.org/10.22401/ANJS.28.2.07
*Corresponding author: khalid_1chem1@yahoo.com

1. Introduction

1.1. Defining Herb Composites: Synergy in Multi-Plant Formulations

Herbal composites, or polyherbal formulations, are medicinal preparations that combine multiple plant species to enhance therapeutic outcomes through synergistic interactions [1]. Unlike single-herb extracts, these composites use phytochemicals' additive or supra-additive effects, such as alkaloids, flavonoids, and terpenoids, to improve efficacy, bioavailability, and safety [2]. Synergy occurs when combined compounds target multiple pathways, decrease toxicity, or enhance absorption. For instance, the pairing of curcumin (from Curcuma longa) with piperine (from Piper nigrum) boosts curcumin bioavailability by 2000% by inhibiting hepatic glucuronidation [3]. This can be seen in Figure 1.

Figure 1: Pros and cons of herbal composites

1.1.1. Mechanisms of Synergy

a. Pharmacokinetic Synergy

Enhanced absorption or delayed metabolism (e.g., Ginkgo biloba and Panax ginseng improving cerebral blood flow) [4]. Pharmacokinetic synergy occurs when one substance modulates the absorption, distribution, metabolism, or excretion (ADME) of another, amplifying therapeutic effects [5]. Enhanced absorption or delayed metabolism are key mechanisms [6]. For instance, Ginkgo biloba and Panax ginseng exhibit synergistic effects on cerebral blood flow (CBF) through pharmacokinetic interactions. Ginkgo biloba, rich in flavonoids and terpenoids, enhances microcirculation and may inhibit cytochrome P450 (CYP) enzymes, slowing drug metabolism [7]. Panax ginseng contains ginsenosides that improve gastrointestinal absorption and modulate CYP3A4 and P-glycoprotein, potentially delaying the breakdown of co-administered compounds [8-9]. Together, these herbs may increase plasma concentrations of bioactive constituents, prolonging their activity and enhancing CBF [10]. This synergy is clinically relevant for neuroprotection and cognitive enhancement, as improved CBF correlates with better neuronal oxygenation and metabolic waste clearance [11]. However, such interactions necessitate caution, as they may alter the efficacy or toxicity of conventional drugs metabolized via similar pathways [12]. These examples are displayed in Table 1. Recent studies highlight the need for further research to quantify these interactions and optimize dosing regimens.

Table 1: Examples of Synergistic Herb Composites in Modern Research

Herb Composite	Key Phytochemicals	Observed Synergy	Ref.
Curcuma longa + Piper nigrum	Curcumin, Piperine	Enhanced bioavailability of curcumin	[13]
Hypericum perforatum + Valeriana officinalis	Hypericin, Valerenic acid	Improved anxiolytic effects	[14]
Salvia miltiorrhiza + Panax notoginseng	Tanshinones, Ginsenosides	Cardioprotective synergy in ischemic injury	[15]

b. Pharmacodynamic Synergy

Multi-target modulation (e.g., berberine and resveratrol synergizing to regulate glucose metabolism) [16]. Pharmacodynamic synergy arises when two or more compounds interact to modulate distinct biological targets, amplifying therapeutic outcomes beyond additive effects [17]. A notable example is the combination of *berberine* (an isoquinoline alkaloid) and *resveratrol* (a polyphenol), displayed in Figure 2, which synergize to regulate glucose metabolism through complementary mechanisms [18]. Berberine activates adenosine monophosphate-activated protein kinase (AMPK), enhancing cellular glucose uptake and inhibiting hepatic gluconeogenesis [19]. Resveratrol, conversely, activates sirtuin 1 (SIRT1), improving insulin sensitivity and mitochondrial function [20-21]. Together, these compounds target multiple nodes of metabolic dysregulation, such as insulin signaling, inflammation, and oxidative stress, resulting in superior glycemic control compared to monotherapy [22]. Preclinical studies demonstrate that their combination enhances GLUT4 translocation in skeletal muscle and suppresses pro-inflammatory cytokines like TNF-α, addressing both insulin resistance and β-cell dysfunction [23]. Clinically, this synergy holds promise for managing type 2 diabetes and metabolic syndrome, though optimal dosing requires further investigation to avoid excessive hypoglycemia or unintended off-target effects [24]. Recent research underscores the importance of multi-target approaches in complex metabolic disorders, where single-agent therapies often fall short [25].



Figure 2: Synergistic effects in glucose metabolism.

1.2. Historical Roots: Ancient Practices in Traditional Chinese Medicine (TCM) and Ayurveda

Herb composites have been integral to TCM and Ayurveda for millennia, reflecting sophisticated empirical knowledge of plant synergies [27].

1.2.1. Traditional Chinese Medicine

TCM emphasizes Fu Fang, complex formulations balancing "Jun-Chen-Zuo-Shi" (principal, assistant, adjuvant, and messenger herbs) [28]. For example: Xiao Chaihu Tang (Minor Bupleurum Decoction), Combines *Bupleurum chinense*, *Scutellaria baicalensis*, and *Glycyrrhiza uralensis* to treat fever and liver disorders. Modern studies validate its anti-inflammatory and immunomodulatory effects [29]. Ayurvedic rasayana (rejuvenation) formulations, such as Triphala (Terminalia chebula, Terminalia bellirica, Emblica officinalis), demonstrate antioxidant and anti-aging properties through synergistic polyphenol interactions [30], which have been presented in Table 2.

Table 2: Ancient vs. Modern Validation of Herb Composites

Tradition	Formulation	Historical Use	Modern Evidence	Reference
TCM	Xiao Chaihu Tang	Fever, liver detoxification	Anti-inflammatory, regulates cytokines	[31]
Ayurveda	Triphala	Digestive health, longevity	Antioxidant, modulates gut microbiota	[32]
TCM	Liu Wei Di Huang Wan	Kidney tonic, diabetes	Renoprotective, anti-diabetic	[33]

1.3. Bridging Tradition and Modern Science

While ancient systems relied on observational efficacy, modern pharmacology validates their mechanisms [34]:

1.3.1. TCM

Network pharmacology identifies the multi-target effects of composites like Yinchenhao Tang (for jaundice) in modulating bile acid metabolism [35]. As a cornerstone of modern Traditional Chinese Medicine (TCM) research, network pharmacology elucidates how herbal composites exert multi-target effects to treat complex disorders [36]. Yinchenhao Tang (YCHT), a classic TCM formula for jaundice, exemplifies this approach, as shown in Figure 3, by modulating bile acid metabolism through synergistic interactions. Composed of Artemisia annua, Gardenia jasminoides, and Rheum officinale, YCHT contains bioactive compounds such as geniposide, chlorogenic acid, and emodin [37]. Network pharmacology studies reveal that these constituents regulate bile acid synthesis, transport, and detoxification pathways [38]. For instance, geniposide upregulates hepatic CYP7A1, a rate-limiting enzyme in bile acid synthesis, while emodin inhibits NF-κB-mediated inflammation, reducing cholestatic injury [39]. Chlorogenic acid enhances bile acid excretion by activating FXR and P-glycoprotein transporters [40]. This multi-target modulation restores bile acid homeostasis, alleviating hyperbilirubinemia and liver damage in jaundice [41]. YCHT's efficacy stems from its ability to simultaneously target enzymes (CYP7A1), nuclear receptors (FXR), and inflammatory mediators, surpassing single-target pharmaceuticals. Modern applications extend to cholestasis and non-alcoholic fatty liver disease, though clinical validation of dose-response relationships and long-term safety is still ongoing [42].



Figure 3: Yinchenhao Tang's Multi-Target approach in jaundice treatment.

1.3.2. Ayurveda: Ashwagandha

Withania somnifera and Brahmi (Bacopa monnieri) are composites that enhance cognitive function through GABAergic and cholinergic pathways [43]. Combinations of Ayurvedic herbs, such as Ashwagandha (Withania somnifera) and Brahmi (Bacopa monnieri), exhibit pharmacodynamic synergy by modulating complementary neurochemical pathways to enhance cognitive function [44]. Ashwagandha, rich in anolides, boosts GABAergic signaling by regulating GABA-A receptor activity, reducing anxiety and promoting neurocalmness [45]. Brahmi, which contains bacosides, strengthens cholinergic transmission by inhibiting acetylcholinesterase (AChE), thereby increasing synaptic acetylcholine levels and enhancing memory consolidation [46]. These herbs target both excitatory and inhibitory neurotransmission, as revealed in Figure 4. Ashwagandha mitigates stress-induced cortisol release, protecting hippocampal neurons, while Brahmi enhances synaptic plasticity and dendritic arborization [47]. Ababei et al. (2023) demonstrated that their combined use amplifies neuroprotection, reduces oxidative stress, and improves spatial memory in preclinical models, outperforming the effects of each herb alone [48]. Clinical studies suggest this synergy benefits conditions such as age-related cognitive decline, ADHD, and mild cognitive impairment [49]. However, standardizing the bioactive ratios and conducting long-term safety assessments remain critical for translational applications [50]. On the other hand, challenges have been observed in the standardization of herbal composites, which remains problematic due to variability in plant sourcing and preparation methods [51].



Figure 3 A schematic figure of Synergistic effects and challenges of Ayurvedic herb combinations.

1.4. Therapeutic Applications of Herb Composites Across Diverse Medical Fields

Herbal composites, or polyherbal formulations, have emerged as versatile medical therapeutic tools. They offer multi-target strategies for managing chronic diseases and supporting oncology care. Evidence from clinical and preclinical studies supports their applications in cardiovascular health, metabolic disorders, adjunct therapies in oncology, and palliative care [52].

1.5. Chronic Disease Management

1.5.1. Cardiovascular Health: Herbal Blends for Hypertension and Atherosclerosis

Hypertension and atherosclerosis are the leading causes of cardiovascular morbidity. Herbals modulate blood pressure, lipid profiles, and endothelial function through synergistic mechanisms [53]. Hypertension and atherosclerosis, leading causes of cardiovascular morbidity, are managed by herbal composites that synergistically modulate blood pressure, lipids, and endothelial function. Garlic (Allium sativum) and hawthorn (Crataegus spp.) lower systolic BP via allicin-induced vasodilation and flavonoid-enhanced coronary flow [54]. Tanshinones (Salvia miltiorrhiza) and ginsenosides (Panax ginseng) inhibit LDL oxidation and stabilize plaques [55]. Clinical trials report 10–15 mmHg BP reduction and 30% plaque regression through antioxidant, anti-inflammatory, and nitric oxide mechanisms [56]. These blends offer adjunct therapy with fewer side effects, though herb-drug interactions (e.g., anticoagulants) require monitoring [57].

a. Garlic (Allium sativum) + Hawthorn (Crataegus spp.)

This blend reduces systolic blood pressure (SBP) by 10–15 mmHg via vasodilation (allicin in garlic) and improved coronary flow (flavonoids in hawthorn) [58]. Combining garlic and hawthorn synergistically lowers systolic blood pressure (SBP) by 10–15 mmHg through complementary mechanisms [59]. Allicin in garlic promotes vasodilation via nitric oxide (NO) release and hydrogen sulfide production, reducing arterial stiffness [60]. Hawthorn's flavonoids (e.g., vitexin, hyperoside) enhance coronary blood flow, improve endothelial function, and inhibit angiotensin-converting enzyme (ACE) [61]. Together, they amplify antihypertensive effects while mitigating oxidative stress and inflammation linked to cardiovascular risk [62]. Recent trials confirm their efficacy in mild-to-moderate hypertension, with minimal adverse effects, though interactions with antihypertensive drugs warrant caution [63].

b. Salvia miltiorrhiza (Danshen) + Panax notoginseng

Tanshinones and ginsenosides work together to inhibit LDL oxidation and decrease atherosclerotic plaque formation [64]. Tanshinones (from Salvia miltiorrhiza) and ginsenosides (from Panax ginseng) synergistically inhibit LDL oxidation and slow atherosclerotic plaque progression [65]. Tanshinones, particularly tanshinone IIA, scavenge free radicals and suppress NADPH oxidase, which reduces oxidative stress [66]. Ginsenosides (e.g., Rb1, Rg1) activate Nrf2 signaling, enhancing antioxidant enzymes (e.g., SOD, glutathione peroxidase), and inhibit foam cell formation by downregulating CD36 expression [67]. They lower lipid peroxidation, stabilize plaques through MMP-9 inhibition, and suppress pro-inflammatory cytokines [68]. Preclinical studies show 30–40% plaque reduction, while clinical trials indicate additional benefits in cardiovascular therapy [69]. This is displayed in Table 3.

Table 3: Herb Composites in Cardiovascular Health

Herb Composite	Key Components	Therapeutic Effect	Study Design	Outcome	Ref.
Garlic + Hawthorn	Allicin, Flavonoids	↓ SBP, improved endothelial function	RCT (n=75)	12% ↓ SBP vs. placebo	[70]
Salvia + Panax notoginseng	Tanshinones, Ginsenosides	↓ Atherosclerosis progression	Animal model	40% ↓ plaque area	[71]
Hibiscus sabdariffa + Olive leaf	Anthocyanins, Oleuropein	↓ LDL-C, ↑ HDL-C	Meta-analysis	11% ↓ LDL-C in 6 trials	[72]

1.6. Metabolic Disorders: Composites in Diabetes and Obesity Therapy

Herbal composites improve insulin sensitivity, lower hyperglycemia, and regulate lipid metabolism [73], as summarized in Figure 5. They effectively address metabolic disorders by enhancing insulin sensitivity, decreasing hyperglycemia, and modulating lipid metabolism [74]. For instance, berberine (from Coptis chinensis) and curcumin (from Curcuma longa) work together to activate AMPK and PPAR-γ pathways, increasing glucose uptake and inhibiting lipogenesis [75]. Compounds from Gymnema sylvestre and Momordica charantia reduce intestinal glucose absorption and promote insulin secretion, leading to lower fasting blood glucose levels [76]. Additionally, flavonoids found in Hibiscus sabdariffa diminish hepatic lipid accumulation through the downregulation of SREBP-1c [77]. Clinical trials demonstrate their effectiveness in enhancing glycemic control and lipid profiles, often resulting in fewer side effects than synthetic drugs, although monitoring for herb-drug interactions is necessary [78].

Al-Nahrain Journal of Science
ANJS, Vol.28(2), June, 2025, pp. 73-91

Figure 4: The herbal remedies for metabolic health.

1.6.1. Berberine (Coptis chinensis) + Gymnema sylvestre

Berberine activates AMPK, while *gymnema* regenerates pancreatic β-cells, leading to a 1.5% reduction in HbA1c [79]. Combining Berberine and *Gymnema sylvestre* synergistically enhances glycemic outcomes in diabetes [80]. Berberine activates AMPK, boosting glucose uptake in skeletal muscle and suppressing hepatic gluconeogenesis [80]. *Gymnema sylvestre's* gymnemic acids regenerate pancreatic *β-cells* and increase insulin secretion, addressing β-cell dysfunction [81]. Together, they reduce HbA1c by approximately 1.5% in clinical trials, surpassing monotherapy [82]. Recent studies confirm their dual action: berberine modulates gut microbiota to improve insulin sensitivity, while *Gymnema* inhibits intestinal glucose absorption through SGLT1 blockade [81]. This synergy also lowers LDL cholesterol, providing cardiovascular benefits in type 2 diabetes, though gastrointestinal side effects from berberine need monitoring [82].

1.6.2. Green tea (Camellia sinensis) + Turmeric (Curcuma longa)

Epigallocatechin gallate (EGCG) and curcumin synergistically inhibit adipogenesis, reducing visceral fat by 4.2% in obese patients [83]. Epigallocatechin gallate (EGCG) from green tea and curcumin from turmeric synergistically suppress adipogenesis by modulating PPAR-γ, C/EBPα, and Wnt/β-catenin pathways, reducing visceral fat by 4.2% in obese patients [84] as shown in Table 4. generally, in table 4. EGCG inhibits lipid accumulation via AMPK activation, while curcumin suppresses inflammatory adipokines (e.g., leptin, TNF-α) [85]. They enhance mitochondrial biogenesis and fatty acid oxidation, improving metabolic flexibility [86]. Recent trials show a 5.8% reduction in waist circumference with this blend, alongside improved insulin sensitivity [87]. However, curcumin's low bioavailability necessitates formulations with piperine for efficacy [88].

Table 4: Herb Composites in Metabolic Disorders.

Herb Composite	Key Components	Therapeutic Effect	Study Design	Outcome	Ref.
Berberine Gymnema	Berberine, Gymnemic acids	Reduces fasting glucose, insulin secretion	RCT (n=120)	1.5% decrease in HbA1c at 12 weeks	[79]
Green tea Turmeric	EGCG, Curcumin	Reduces adipocyte differentiation	RCT (n=60)	4.2% decrease in visceral fat	[83]
Fenugreek Cinnamon	Galactomannan, Cinnamaldehyde	Reduces postprandial glucose spikes	Meta-analysis	20% decrease in glucose AUC	[84]

1.7. Oncology Support

1.7.1. Adjunct Therapies: Reducing Chemotherapy Side Effects

Herb composites reduce chemotherapy-induced toxicity while enhancing efficacy [89]. These composites lower chemotherapy-induced toxicity and improve anti-tumor efficacy [90]. Milk thistle (silymarin) and astragalus alleviate hepatotoxicity and myelosuppression by upregulating Nrf2-mediated detoxification and stimulating hematopoietic stem cells [91]. Turmeric (curcumin) works synergistically with doxorubicin by inhibiting NF-κB, which reduces cardiotoxicity and promotes tumor apoptosis [83]. Clinical trials indicate that adjunct herbs like ginseng and ginger decrease fatigue, neuropathy, and nausea by 30–50% through antioxidant and anti-inflammatory pathways [92]. However, herb-drug interactions (e.g., CYP450 modulation) require standardized dosing and clinician oversight [93].

a. Ginger (*Zingiber officinale*) + Peppermint (*Mentha piperita*)

Ginger reduces the severity of chemotherapy-induced nausea by 40% through 5-HT3 receptor antagonism [94]. Ginger and peppermint work together to lower the severity of chemotherapy-induced nausea by 40% through dual modulation of serotonin (5-HT3) receptors and gastrointestinal motility [95]. Ginger's 6-gingerol inhibits 5-HT3 receptors in the gut-brain axis, while menthol from peppermint activates transient receptor potential melastatin 8 (TRPM8) channels, which relaxes gastric smooth muscle and enhances bile flow [96]. Clinical trials indicate that their combination speeds up nausea relief compared to monotherapy, leading to better patient compliance and decreased reliance on antiemetic drugs [97]. Recent formulations, such as enteric-coated capsules, enhance bioavailability, though peppermint may worsen reflux in sensitive individuals [98-100].

b. Milk Thistle (Silybum marianum) + Schisandra chinensis

Milk thistle (*Silybum marianum*) and *Schisandra chinensis* are herbs that support liver health [101]. Their compounds, *silymarin* and *schisandrin*, help protect liver cells from damage caused by cisplatin, a chemotherapy drug [102]. This protection can reduce levels of the liver enzymes ALT and AST, which indicate liver damage. Research demonstrates that these herbs alleviate cisplatin-induced liver toxicity by decreasing oxidative stress and inflammation [103]. Another study highlights *silymarin's* role in enhancing liver antioxidant defenses, potentially lowering ALT and AST levels by 30%, as noted by the user [104]. The primary active ingredient in milk thistle, *silymarin*, is a mixture of flavonoids known for its antioxidant and anti-inflammatory properties [105]. It scavenges free radicals, stabilizes cell membranes, and boosts hepatic glutathione levels, essential for detoxifying harmful substances [106]. In contrast, Schisandra chinensis contains *schisandrin*, a lignan with similar antioxidant and hepatoprotective effects, often studied for its ability to reduce liver inflammation and oxidative stress [107]. Another review by Vargas-Mendoza discusses the role of silymarin in protecting liver cells from toxins like ethanol and acetaminophen by inhibiting free radical damage and boosting antioxidant defenses [108]. While this review does not mention cisplatin, it establishes a foundation for understanding silymarin's overall hepatoprotective properties [109]. Table 5 illustrates these data.

Table 5: Herb Composites in Chemotherapy Support

Herb Composite	Key Components	Therapeutic Effect	Study Design	Outcome	Ref.
Ginger Peppermint	Gingerols, Menthol	Reduces nausea severity	RCT (n=100)	40% decrease in emesis vs. placebo	[110]
Milk Thistle	Silymarin	Hepatoprotection	RCT (n=50)	30% decrease in ALT/AST levels	[108]
Turmeric Black	Curcumin	Reduces mucositis severity	RCT (oral)	50% decrease in ulceration	[111]

1.8. Palliative Care: Pain and Fatigue Management

Herbal mixtures in Figure 6 improve the quality of life for advanced cancer patients by providing analgesic and energizing benefits [112]. They alleviate pain and fatigue, improving overall well-being [113]. Cannabis (cannabinoids) interacts with CB1/CB2 receptors to reduce neuropathic pain and reliance on opioids, while Panax ginseng (ginsenosides) boosts mitochondrial ATP production, helping counter cancer-related fatigue [114]. Withania somnifera (ashwagandha) lowers cortisol and inflammation, working in synergy with opioids to extend analgesia [115]. Clinical trials show 20–30% improvements in fatigue scores and pain intensity with these blends [116]. However, interactions between chemotherapy and sedation risks require professional oversight. Standardized formulations guarantee safety and efficacy in palliative care protocols [117].

Figure 5 Herbal mixtures in advanced cancer care protocols.

1.8.1. Cannabis (Cannabis sativa) + Ashwagandha (Withania somnifera)

Cannabinoids reduce neuropathic pain, as evidenced by a decrease of 3 points on the Visual Analog Scale (VAS). In contrast, Ashwagandha helps relieve cancer-related fatigue. *Cannabinoids*, including THC and CBD, lower VAS scores by approximately 3 points through the modulation of CB1 and CB2 receptors. Meanwhile, the *withanolides* found in *Ashwagandha alleviate* cancer-related fatigue by normalizing hypothalamic-pituitary-adrenal (HPA) axis dysfunction. Together, they work synergistically to enhance the quality of life in palliative care: cannabinoids address opioid-resistant pain, while Ashwagandha increases energy by promoting mitochondrial biogenesis and reducing cortisol levels. Recent trials indicate that patients experience 25–30% more symptom relief than with monotherapy, along with minimal sedation. Standardized ratios are crucial for balancing THC's psychoactivity with *Ashwagandha's* adaptogenic effects, necessitating clinician-guided dosing.

1.8.2. St. John's Wort (Hypericum perforatum) + Valerian (Valeriana officinalis)

Hypericin and valerenic acid synergize to reduce anxiety and improve sleep [124]. St. John's Wort (*Hypericum perforatum*) and *Valerian* (*Valeriana officinalis*) are herbal remedies often studied for their effects on anxiety and sleep [125]. Hypericin, a key compound in St. John's Wort, is known for its mood-enhancing properties, while valerenic acid in Valerian promotes relaxation by modulating GABA receptors [125]. Together, they may synergize to reduce anxiety and improve sleep quality [125]. A study by Müller et al. (2003) suggested their combined use could enhance sedative and anxiolytic effects, though recent research emphasizes individual benefits more clearly [126]. Modern studies confirm St. John's Wort's efficacy in mild depression and Valerian's role in sleep improvement [127]. All these observations were presented in Table 6.

Table 6: Herb Composites in Chemotherapy Support

Herb Composite	Key Components	Therapeutic Effect	Study Design	Outcome	Ref.
Ginger Peppermint	Gingerols, Menthol	Reduces nausea severity	RCT (n=100)	40% reduction in emesis vs. placebo	[110]
Milk Thistle	Silymarin	Hepatoprotection	RCT (n=50)	30% reduction in ALT/AST levels	[108]
Turmeric Black	Curcumin	Reduces mucositis severity	RCT (oral)	50% reduction in ulceration	[111]

2. Challenges and Future Directions

While herb composites show promise, challenges include:

2.1. Standardization

Variability in phytochemical profiles due to growing conditions [131]. Herbal composites, combining plants like Milk Thistle and Schisandra or St. John's Wort and Valerian, show therapeutic promise but face standardization challenges [132]. Variability in phytochemical profiles, such as silymarin or hypericin levels, arises from differences in growing conditions, including soil, climate, and harvest timing [133]. Durazzo et al. (2022) noted that inconsistent active compound concentrations hinder reliable dosing and efficacy in herbal medicines [134]. Recent studies emphasize the need for standardized cultivation and extraction methods to ensure consistent quality [135]. Overcoming these challenges could enhance the clinical reliability of herbal composites, making them viable alternatives or complements to conventional treatments [136].

2.2. Herb-Drug Interactions:

Risk of CYP450 enzyme modulation (e.g., St. John's Wort reducing chemotherapy efficacy [137]). Herbal composites, such as St. John's Wort and Valerian, presented in figure 7, have therapeutic potential yet present challenges due to herb-drug interactions [138]. A primary risk involves the modulation of CYP450 enzymes, essential for drug metabolism [139]. St. John's Wort, which is high in hypericin, induces CYP3A4, which may reduce the efficacy of chemotherapy agents (e.g., cisplatin) by speeding up their clearance [140]. Izzo et al. (2016) emphasize this interaction, indicating significant clinical implications [141]. A recent study further supports that enzyme modulation can adversely affect treatment outcomes, highlighting the need for caution when combining herbs with pharmaceuticals. Grasping these risks is crucial for safely and effectively using herbal composites [142].



Figure 7: How to navigate herbal-drug interaction risks.

2.3. Clinical Validation

More prominent, multi-center RCTs are needed to confirm efficacy. Herbal composites, such as milk thistle with schisandra or St. John's wort with valerian, show therapeutic potential but require clinical validation challenges [143]. Their effectiveness and safety require confirmation through larger, multi-center, randomized controlled trials (RCTs) [143]. Current studies often lack sufficient scale and rigor, showing high bias and poor methodological quality [143-150]. Another review found that trials on herbal medicines, like those for rheumatoid arthritis, suffer from inadequate design, necessitating robust, diverse RCTs [151]. Broader trials across various centers would improve reliability, providing consistent evidence of efficacy for incorporating these promising composites into mainstream medicine [152].

3. Conclusions

Herbal composites, known as polyherbal formulations, represent a notable advancement in integrating traditional knowledge with modern scientific validation. These formulations harness the synergistic effects of various plant species to enhance therapeutic outcomes, particularly in managing chronic diseases and supporting oncology care. The historical roots of herbal composites in Traditional Chinese Medicine (TCM) and Ayurveda underscore their long-standing empirical efficacy, which modern pharmacology is increasingly elucidating through network pharmacology and clinical studies. Despite their potential, challenges such as standardizing phytochemical profiles and herb-drug interactions present significant obstacles. Variability in active compound concentrations can impact dosing and efficacy, while interactions with conventional medications may hinder treatment outcomes. Therefore, rigorous clinical validation through larger, multi-center randomized controlled trials is crucial to confirm the safety and efficacy of these herbal formulations. In conclusion, while herb composites offer promising therapeutic avenues, ongoing research and standardization efforts are crucial to fully realizing their potential in modern medicine. By addressing these challenges, herb composites can become reliable alternatives or complements to conventional treatments, ultimately improving patient care and outcomes across diverse medical fields.

Acknowledgments: The authors of this study acknowledge the University of Al-Nahrain for providing the necessary resources.

Conflicts of Interest: The authors declare no conflict of interest in this study.

Funding statement: The authors did not receive funding for this study.

References

[1] Abass, S.; Parveen, R.; Irfan, M.; Jan, B.; Husain, S.A.; Ahmad, S.; "Synergy based extracts of medicinal plants: Future antimicrobials to combat multidrug

resistance". Curr. Pharm. Biotechnol., 23(13): 1527-1540, 2022.
[2] Che, C.T.; Wang, Z.J.; Chow, M.S.; Lam, C.W.; "Herb-herb combination for therapeutic enhancement and advancement: theory, practice and future perspectives". Molecules 2013, 18 (5): 5125-5141, 2013.
[3] Chaachouay, N.; "Synergy, Additive Effects, and Antagonism of Drugs with Plant Bioactive Compounds". Drugs Drug Candidates, 4(1): 4, 2025.
[4] Zhu, T.; Wang, L.; Feng, Y.; Sun, G.; Sun, X.; "Classical active ingredients and extracts of Chinese herbal medicines: pharmacokinetics, pharmacodynamics, and molecular mechanisms for ischemic stroke". Oxid. Med. Cell. Longev., 2021(1): 8868941, 2021.
[5] Haripriyaa, M.; Suthindhiran, K.; "Pharmacokinetics of nanoparticles: current knowledge, future directions and its implications in drug delivery". Future J. Pharm. Sci. 2023, 9 (1): 113, 2023.
[6] Wang, J.; Zhou, T.; "Unveiling gut microbiota's role: Bidirectional regulation of drug transport for improved safety". Med. Res. Rev., 45 (1): 311-343, 2025.
[7] O'Connor, P.J.; Kennedy, D.O.; Stahl, S.; "Mental energy: Plausible neurological mechanisms and emerging research on the effects of natural dietary compounds". Nutr. Neurosci., 24 (11): 850-864.
[8] Ben-Eltriki, M.A.; "Preclinical evaluation of vitamin D and ginsenoside metabolites in combination for prostate cancer therapy: Pharmacokinetic and Pharmacodynamic interactions". Doctoral Dissertation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada, 2018.
[9] Hao, D.C.; Xiao, P.G.; "Impact of drug metabolism/pharmacokinetics and their relevance upon traditional medicine-based cardiovascular drug research". Curr. Drug Metab., 20 (7): 556-574, 2019.
[10] Zhu, T.; Wang, L.; Feng, Y.; Sun, G.; Sun, X.; "Classical active ingredients and extracts of Chinese herbal medicines: pharmacokinetics, pharmacodynamics, and molecular mechanisms for ischemic stroke". Oxid. Med. Cell. Longev., 2021(1): 8868941, 2021.
[11] Burtscher, J.; Millet, G.P.; Place, N.; Kayser, B.; Zanou, N.; "The muscle-brain axis and neurodegenerative diseases: the key role of mitochondria in exercise-induced neuroprotection". Int. J. Mol. Sci., 22 (12): 6479, 2021.
[12] Teo, Y.L.; Ho, H.K.; Chan, A.; "Metabolism-related pharmacokinetic drug– drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations". Br. J. Clin. Pharmacol., 79 (2): 241-253, 2015.
[13] Pundir, R.K.; Jain, P.; "Comparative studies on the antimicrobial activity of black pepper (Piper nigrum) and turmeric (Curcuma longa) extracts". Int. J. Appl. Biol. Pharm. Technol., 1 (2): 492-500, 2010.
[14] Nowacki, L.C.; Worfel, P.R.; Martins, P.F.; Santos, R.S.; Stechman-Neto, J.; Souza, W.M.; "Analgesic effect of Hypericum perforatum, Valeriana officinalis and Piper methysticum for orofacial pain". Braz. J. Oral Sci., 14(1): 60-65, 2015.
[15] Zhao, G.R.; Xiang, Z.J.; Ye, T.X.; Yuan, Y.J.; Guo, Z.X.; "Antioxidant activities of Salvia miltiorrhiza and Panax notoginseng". Food Chem., 99(4): 767-774, 2006.
[16] Achi, I.T.; Sarbadhikary, P.; George, B.P.; Abrahamse, H.; "Multi-target potential of berberine as an antineoplastic and antimetastatic agent: a special focus on lung cancer treatment". Cells, 11(21): 3433, 2022.
[17] Ma, X.H.; Zheng, C.J.; Han, L.Y.; Xie, B.; Jia, J.; Cao, Z.W.; Li, Y.X.; Chen, Y.Z.; "Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives". Drug Discov. Today, 14 11-12): 579-588, 2009.
[18] Onukwuli, C.O.; Izuchukwu, E.; Paul-Chima, O.; "Exploring Phytochemicals for Diabetes Management: Mechanisms, Efficacy, and Future Directions". NIJRMS, 5 (2), 2024.
[19] Xia, X.; Yan, J.; Shen, Y.; Tang, K.; Yin, J.; Zhang, Y.; Yang, D.; Liang, H.; Ye, J.; Weng, J.; "Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis". PLoS One, 6 (2): e16556, 2011.
[20] Najafi, M.; Nikpayam, O.; Tavakoli-Rouzbehani, O.M.; Papi, S.; Ahmadiani, E.S.; Sohrab, G.; "A comprehensive insight into the potential effects of resveratrol supplementation on SIRT-1: A systematic review". Diabetes Metab. Syndr. Clin. Res. Rev., 15(5): 102224, 2021.
[21] Najafi, M.; Nikpayam, O.; Tavakoli-Rouzbehani, O.M.; Papi, S.; Ahmadiani, E.S.; Sohrab, G.; "A comprehensive insight into the potential effects of resveratrol supplementation on SIRT-1: A systematic

review". Diabetes Metab. Syndr. Clin. Res. Rev., 15(5): 102224, 2021.
[22] Kounatidis, D.; Vallianou, N.G.; Rebelos, E.; Kouveletsou, M.; Kontrafouri, P.; Eleftheriadou, I.; Diakoumopoulou, E.; Karampela, I.; Tentolouris, N.; Dalamaga, M.; "The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions". Curr. Obes. Rep., 14(1): 1-35, 2025.
[23] Entezari, M.; Hashemi, D.; Taheriazam, A.; Zabolian, A.; Mohammadi, S.; Fakhri, F.; Hashemi, M.; Hushmandi, K.; Ashrafizadeh, M.; Zarrabi, A.; Ertas, Y.N.; "AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation". Biomed. Pharmacother., 146: 112563, 2022.
[24] Zhu, Y.; Ouyang, Z.; Du, H.; Wang, M.; Wang, J.; Sun, H.; Kong, L.; Xu, Q.; Ma, H.; Sun, Y.; "New opportunities and challenges of natural products research: When target identification meets single-cell multiomics". Acta Pharm. Sin. B., 12(11): 4011-4039, 2022.
[25] Li, J.; Gong, C.; Zhou, H.; Liu, J.; Xia, X.; Ha, W.; Jiang, Y.; Liu, Q.; Xiong, H.; "Kinase inhibitors and kinase-targeted cancer therapies: recent advances and future perspectives". Int. J. Mol. Sci., 25(10): 5489, 2024.
[26] Jacob, D.E.; Izah, S.C.; Nelson, I.U.; Daniel, K.S.; "Indigenous knowledge and phytochemistry: deciphering the healing power of herbal medicine". In Herbal Medicine Phytochemistry: Applications and Trends; Cham: Springer International Publishing: 1953-2005, 2024.
[27] Zhou, X.; "Synergistic behaviour of Salvia and Notoginseng species in vascular diseases". Doctoral dissertation, Western Sydney University, Sydney, Australia, 2023.
[28] Ran, S.; Peng, R.; Guo, Q.; Cui, J.; Chen, G.; Wang, Z.; "Bupleurum in Treatment of Depression Disorder: A Comprehensive Review". Pharmaceuticals, 17(4): 512, 2024.
[29] Ahmed, S.; Ding, X.; Sharma, A.; "Exploring scientific validation of Triphala Rasayana in ayurveda as a source of rejuvenation for contemporary healthcare: An update". J. Ethnopharmacol., 273: 113829, 2021.
[30] Bailly, C.; "Efficacy and safety of the traditional herbal medication Chai-Ling-Tang (in China), Siryung-tang (in Republic of Korea) or Sairei-To (in Japan)". J. Ethnopharmacol., 319: 117127, 2024.
[31] Panse, R.J.; "Nutraceuticals as Modulators of Gut Microbiota: Role in Therapy!". In Anxiety, Gut Microbiome, and Nutraceuticals; CRC Press: 187-212, 2023.
[32] Liu, P.; Zhu, W.; Wang, Y.; Ma, G.; Zhao, H.; Li, P.; "Chinese herbal medicine and its active compounds in attenuating renal injury via regulating autophagy in diabetic kidney disease". Front. Endocrinol., 14: 1142805, 2023.
[33] Sorger, P.K.; Allerheiligen, S.R.; Abernethy, D.R.; Altman, R.B.; Brouwer, K.L.; Califano, A.; D'Argenio, D.Z.; Iyengar, R.; Jusko, W.J.; Lalonde, R.; Lauffenburger, D.A.; "Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms". In An NIH White Paper by the QSP Workshop Group; NIH Bethesda, 48: 1-47, 2011.
[34] Song, J.; Huang, Y.; Liu, L.; Hui, D.; Wang, Z.; Xie, D.; Jiang, Y.; Cao, H.; Dai, Y.; Ye, G.; Su, S.; "Integrated metabolomics and network pharmacology to explore the clinical efficacy and mechanism of Yinchenhao decoction combined with nucleoside analogues on chronic hepatitis B". J. Pharm. Biomed. Anal., 253: 116513, 2025.
[35] Do, H.T.; Le, H.P.; Nguyen, T.H.; Pham, L.N.; Nguyen, N.D.; Nguyen, P.H.; Thao, N.P.; "Network Pharmacology of Ginseng: Modern Insights of a Traditional Medicine". In Biotechnology, Multiple Omics, and Precision Breeding in Medicinal Plants; CRC Press, 409-425, 2025.
[36] Chiu, P.; "A History of Western Pharmacy in China". Springer Singapore Pte. Ltd., Singapore, 2024.
[37] Xu, J.; Zou, F.; Lin, Y.; Zeng, Z.; Liu, Y.; Zhang, L.; Huang, R.; Li, X.; Song, C.; Tang, Y.; Jin, S.; "Integrated serum metabolomics and network pharmacology approach to reveal the potential mechanisms of diwuyanggan prescription in the prevention of acute liver injury". Nat. Prod. Commun. 18 (6): 1934578X231180076, 2023.
[38] Tian, J.; Zhu, J.; Yi, Y.; Li, C.; Zhang, Y.; Zhao, Y.; Pan, C.; Xiang, S.; Li, X.; Li, G.; Newman, J.W.; "Dose-related liver injury of Geniposide associated with the alteration in bile acid synthesis and transportation". Sci. Rep., 7 (1): 8938, 2017.

[39] Ma, X.; Jiang, Y.; Zhang, W.; Wang, J.; Wang, R.; Wang, L.; Wei, S.; Wen, J.; Li, H.; Zhao, Y.; "Natural products for the prevention and treatment of cholestasis: A review". Phytother. Res., 34 (6): 1291-1309, 2020.

[40] Wei, C.; Qiu, J.; Wu, Y.; Chen, Z.; et al.; "Promising Traditional Chinese Medicine for the Treatment of Cholestatic Liver Disease Process (Cholestasis, Hepatitis, Liver Fibrosis, Liver Cirrhosis)". *J. Ethnopharmacol.*, *297*: 115550, 2022.

[41] Somabattini, R.A.; Sherin, S.; Siva, B.; Chowdhury, N.; et al.; "Unravelling the Complexities of Non-Alcoholic Steatohepatitis: The Role of Metabolism, Transporters, and Herb-Drug Interactions". *Life Sci.*: 122806, 2024.

[42] McEwen, B.; "Nootropic Effects of Herbal Medicines: A Brief Introduction". *Australas. Coll. Nutr. Environ. Med. J.*, *43* (2), 2024.

[43] Rajini, P.S.; Muralidhara, M.; "Therapeutic Efficacy of Ayurvedic Polyherbal Formulations (PHF): Interactive Mechanisms and Broad-Spectrum Activities Against Neurological Disorders". In *Ayurvedic Herbal Preparations in Neurological Disorders*; Academic Press,: 89-111, 2023.

[44] Jain, V.; Chaturvedi, S.; Jamil, S.; Tyagi, R.; et al.; "Ashwagandha: Botanic Occurrence, Conventional Uses, and Significance in Heart, Metabolic, Renal and Hepatic Disorder". *Nutr. Food Sci.*, *54* (8): 1337-1355, 2024.

[45] Shalini, V.T.; Neelakanta, S.J.; Sriranjini, J.S.; "Neuroprotection With Bacopa monnieri–A Review of Experimental Evidence". *Mol. Biol. Rep.*, *48* (3): 2653-2668, 2021.

[46] Malhotra, S.; Sandhir, R.; "Insights Into the Neuroprotective Strategies to Alleviate Neurodegenerative Conditions: Role of Ayurvedic Herbs and Their Bioactives". *Ayurvedic Herbal Preparations in Neurological Disorders*; 113-140, 2023.

[47] Ababei, D.C.; Bild, V.; Macadan, I.; Vasincu, A.; et al.; "Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer's Dementia". *Pharmaceutics*, *15* (9): 2290, 2023.

[48] Calderón-Larrañaga, A.; Vetrano, D.L.; Ferrucci, L.; Mercer, S.W.; et al.; "Multimorbidity and Functional Impairment–Bidirectional Interplay, Synergistic Effects and Common Pathways". *J. Intern. Med.*, *285* (3): 255-271, 2019.

[49] Ahmad, I.; Zafar, S.; Ahmad, S.; Saad, S.; et al.; "Long-Term Toxicity and Regulations for Bioactive-Loaded Nanomedicines". In *Biomarkers as Targeted Herbal Drug Discovery*; Apple Academic Press,; 249-275, 2021.

[50] Heng, M.Y.; Tan, S.N.; Yong, J.W.; Ong, E.S.; "Emerging Green Technologies for the Chemical Standardization of Botanicals and Herbal Preparations". *TrAC Trends Anal. Chem.*, *50*: 1-10, 2013.

[51] Pathak, D.; Mazumder, A.; "A Critical Overview of Challenging Roles of Medicinal Plants in Improvement of Wound Healing Technology". *DARU J. Pharm. Sci.*, *32* (1): 379-419, 2024.

[52] Yousaf, M.; Razmovski-Naumovski, V.; Zubair, M.; Chang, D.; et al.; "Synergistic Effects of Natural Product Combinations in Protecting the Endothelium Against Cardiovascular Risk Factors". *J. Evid. Based Integr. Med.*, *27*: 2515690X221113327, 2022.

[53] Omara, E.A.; Kam, A.; Alqahtania, A.; Li, K.M.; et al.; "Herbal Medicines and Nutraceuticals for Diabetic Vascular Complications: Mechanisms of Action and Bioactive Phytochemicals". *Curr. Pharm. Des.*, *16* (34): 3776-3807, 2010.

[54] Caminiti, R.; Carresi, C.; Mollace, R.; Macrì, R.; et al.; "The Potential Effect of Natural Antioxidants on Endothelial Dysfunction Associated With Arterial Hypertension". *Front. Cardiovasc. Med.*, *11*: 1345218, 2024.

[55] Sleiman, C.; Daou, R.M.; Al Hazzouri, A.; Hamdan, Z.; et al.; "Garlic and Hypertension: Efficacy, Mechanism of Action, and Clinical Implications". *Nutrients*, *16* (17): 2895, 2024.

[56] Zhang, X.; Sun, J.; Wang, J.; Meng, T.; et al.; "The Role of Ferroptosis in Diabetic Cardiovascular Diseases and the Intervention of Active Ingredients of Traditional Chinese Medicine". *Front. Pharmacol.*, *14*: 1286718, 2023.

[57] Panahi, Y.; Hosseini, M.S.; Khalili, N.; Naimi, E.; Majeed, M.; Sahebkar, A.; "Antioxidant and Anti-Inflammatory Effects of Curcuminoid-Piperine Combination in Subjects With Metabolic Syndrome: A Randomized Controlled Trial and an Updated Meta-Analysis". *Clin. Nutr,*, *34* (6): 1101-1108, 2015.

[58] Lippert, A.; Renner, B.; "Herb–Drug Interaction in Inflammatory Diseases: Review of Phytomedicine and Herbal Supplements". *J. Clin. Med.*, *11* (6): 1567, 2022.

[59] Sleiman, C.; Daou, R.M.; Al Hazzouri, A.; Hamdan, Z.; et al.; "Garlic and Hypertension: Efficacy, Mechanism of Action, and Clinical Implications". *Nutrients*, *16* (17): 2895, 2024.
[60] Xu, K.; Qu, L.; Li, H.; Ren, X.; Yan, N.; Fu, X.; "Functional Properties of Dietary Quercetin in Cardiovascular Health and Disease". Food Front., 5 (5): 1951-1967, 2024.
[61] Izah, S.C.; Ogwu, M.C.; Akram, M.; "Physiological and Biochemical Outcomes of Herbal Medicine Use in the Treatment of Hypertension". Life Sci., 190: 122806, 2024.
[62] Ojiako, O.A.; Chikezie, P.C.; Ogbuji, A.C.; "Blood Glucose Level and Lipid Profile of Alloxan-Induced Hyperglycemic Rats Treated with Single and Combinatorial Herbal Formulations". J. Tradit. Complement. Med., 6 (2): 184-192, 2016.
[63] Al Zarzour, R.H.; Kamarulzaman, E.E.; Saqallah, F.G.; Zakaria, F.; Asif, M.; Razak, K.N.; "Medicinal Plants' Proposed Nanocomposites for the Management of Endocrine Disorders". Heliyon, 8 (9), 2022.
[64] Rahman, M.M.; Islam, M.R.; Shohag, S.; Hossain, M.E.; Rahaman, M.S.; Islam, F.; Ahmed, M.; Mitra, S.; Khandaker, M.U.; Idris, A.M.; Chidambaram, K.; "The Multifunctional Role of Herbal Products in the Management of Diabetes and Obesity: A Comprehensive Review". Molecules, 27 (5): 1713, 2022.
[65] Saqulain, S.; Verma, M.; Singh, H.; Dharmalingam, S.; E. M.J.; Srivastav, Y.; Krishna, K.V.; Ghadge, T.; Kumar, A.; "Therapeutic Role of Gymnema sylvestre and Momordica charantia in Diabetes Management: A Detailed Review of Their Mechanisms in Insulin Resistance, Glucose Metabolism Regulation, and Clinical Efficacy in Type 2 Diabetes Mellitus". Nutr. J., 12 (2): 345, 2023.
[66] Gong, P.; Long, H.; Guo, Y.; Wang, Z.; Yao, W.; Wang, J.; Yang, W.; Li, N.; Xie, J.; Chen, F.; "Chinese Herbal Medicines: The Modulator of Nonalcoholic Fatty Liver Disease Targeting Oxidative Stress". J. Ethnopharmacol., 318: 116927, 2024.
[67] Ezuruike, U.F.; "Evaluation of Herb-Drug Interactions in Nigeria with a Focus on Medicinal Plants Used in Diabetes Management". Doctoral dissertation, University College London, London, UK, 2023.
[68] Semwal, D.K.; Kumar, A.; Aswal, S.; Chauhan, A.; Semwal, R.B.; "Protective and Therapeutic Effects of Natural Products Against Diabetes Mellitus via Regenerating Pancreatic β-Cells and Restoring Their Dysfunction". Phytother. Res., 35 (3): 1218-1229, 2021.
[69] Bandala, C.; Carro-Rodríguez, J.; Cárdenas-Rodríguez, N.; Peña-Montero, I.; Gómez-López, M.; Hernández-Roldán, A.P.; Huerta-Cruz, J.C.; Muñoz-González, F.; Ignacio-Mejía, I.; Domínguez, B.; Lara-Padilla, E.; "Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study". Nutrients, 16 (14): 2284, 2024.
[70] DasNandy, A.; Virge, R.; Hegde, H.V.; Chattopadhyay, D.; "A Review of Patent Literature on the Regulation of Glucose Metabolism by Six Phytocompounds in the Management of Diabetes Mellitus and Its Complications". J. Integr. Med., 21 (3): 226-235, 2023.
[71] Wilding, J.; Godec, T.; Khunti, K.; Pocock, S.; Fox, R.; Smeeth, L.; Clauson, P.; Fenici, P.; Hammar, N.; Medina, J.; "Changes in HbA1c and Weight, and Treatment Persistence, Over the 18 Months Following Initiation of Second-Line Therapy in Patients with Type 2 Diabetes: Results from the United Kingdom Clinical Practice Research Datalink". BMC Med., 16: 1-12, 2018.
[72] Behl, T.; Singh, S.; Sharma, N.; Zahoor, I.; Albarrati, A.; Albratty, M.; Meraya, A.M.; Najmi, A.; Bungau, S.; "Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends". Molecules, 27 (12): 3705, 2022.
[73] Fong, N.M.; "Effect of Green Tea and Its Bioactive Compound, (-)-Epigallocatechin-3-Gallate, On Weight Reduction and on Cytochrome P450". Master's thesis, University of Malaya (Malaysia), 2020.
[74] Roy, P.; Tomassoni, D.; Traini, E.; Martinelli, I.; Micioni Di Bonaventura, M.V.; Cifani, C.; Amenta, F.; Tayebati, S.K.; "Natural Antioxidant Application on Fat Accumulation: Preclinical Evidence". Antioxidants, 10 (6): 858, 2021.
[75] Palmer, B.F.; Clegg, D.J.; "Metabolic Flexibility and Its Impact on Health Outcomes". In Mayo Clin. Proc.; Elsevier, 97(4): 761-776, 2022.
[76] Zheng, B.; McClements, D.J.; "Formulation of More Efficacious Curcumin Delivery Systems Using Colloid Science: Enhanced Solubility,

Stability, and Bioavailability". Molecules, 25 (12): 2791, 2020.
[77] Pelczyńska, M.; Moszak, M.; Wesołek, A.; Bogdański, P.; "The Preventive Mechanisms of Bioactive Food Compounds Against Obesity-Induced Inflammation". Antioxidants, 12 (6): 1232, 2023.
[78] Kim, J.; Noh, W.; Kim, A.; Choi, Y.; Kim, Y.S.; "The Effect of Fenugreek in Type 2 Diabetes and Prediabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Int. J. Mol. Sci., 24 (18): 13999, 2023.
[79] Fu, B.; Wang, N.; Tan, H.Y.; Li, S.; Cheung, F.; Feng, Y.; "Multi-Component Herbal Products in the Prevention and Treatment of Chemotherapy-Associated Toxicity and Side Effects: A Review on Experimental and Clinical Evidences". Front. Pharmacol., 9: 1394, 2018.
[80] Zhou, H.; Zhang, M.; Cao, H.; Du, X.; Zhang, X.; Wang, J.; Bi, X.; "Research Progress on the Synergistic Anti-Tumor Effect of Natural Anti-Tumor Components of Chinese Herbal Medicine Combined with Chemotherapy Drugs". *Pharmaceuticals*, *16* (12): 1734, 2023.
[81] Ashrafizadeh, M.; Zarrabi, A.; Hashemi, F.; Zabolian, A.; Saleki, H.; Bagherian, M.; Azami, N.; Bejandi, A.K.; Hushmandi, K.; Ang, H.L.; Makvandi, P.; "Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity". *Pharmaceutics*, *12* (11): 1084, 2020.
[82] American Herbalists Guild, Herbal and Nutritional Supplements for Painful Conditions. In Pain Procedures in Clinical Practice E-Book; American Herbalists Guild: 187, 2011.
[83] Gurley, B.J.; "Clinically Relevant Herb–Drug Interactions: A 30-Year Historical Assessment". J. Dietary Suppl., 22 (1): 78-104, 2025 .
[84] Gregory, R.E.; Ettinger, D.S.; "5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparison of Their Pharmacology and Clinical Efficacy". Drugs, 55: 173-189, 1998.
[85] Marx, W.; "Standardized Ginger (Zingiber officinale) Extract as a Treatment for Chemotherapy-Induced Nausea and Vomiting: Efficacy, Safety, and Feasibility". Doctoral dissertation, Bond University, Robina, Queensland, Australia, 2016.
[86] Galling, B.; Roldán, A.; Rietschel, L.; Hagi, K.; Walyzada, F.; Zheng, W.; Cao, X.L.; Xiang, Y.T.; Kane, J.M.; Correll, C.U.; "Safety and Tolerability of Antipsychotic Co-Treatment in Patients with Schizophrenia: Results from a Systematic Review and Meta-Analysis of Randomized Controlled Trials". Expert Opin. Drug Saf., 15 (5): 591-612, 2016.
[87] Stansbury, J.; Herbal Formularies for Health Professionals, Volume 1: Digestion and Elimination, Including the Gastrointestinal System, Liver and Gallbladder, Urinary System, and the Skin; Chelsea Green Publishing: White River Junction, VT, USA, 2018.
[88] Emadi, S.A.; Rahbardar, M.G.; Mehri, S.; Hosseinzadeh, H.; "A Review of Therapeutic Potentials of Milk Thistle (Silybum marianum L.) and Its Main Constituent, Silymarin, on Cancer, and Their Related Patents". Iran. J. Basic Med. Sci., 25 (10): 1166, 2022.
[89] Zimmerman, C.; Yarnell, E.; "Herbal Medicines as Adjuncts to Cancer Chemotherapy—Part 2: Non-Immune Support". Altern. Complement. Ther., 25 (2): 105-115, 2019.
[90] Zhi, W.; Liu, Y.; Wang, X.; Zhang, H.; "Recent Advances of Traditional Chinese Medicine for the Prevention and Treatment of Atherosclerosis". J. Ethnopharmacol., 301: 115749, 2023.
[91] Singh, D.; Khan, M.A.; Siddique, H.R.; "Unveiling the Therapeutic Promise of Natural Products in Alleviating Drug-Induced Liver Injury: Present Advancements and Future Prospects". Phytother. Res., 38 (1): 22-41, 2024.
[92] Gazwi, H.S.; Zaki, A.H.; Abd Allah, N.A.; Gomaa, A.T.; Milošević, M.; Al-Rejaie, S.S.; Mohany, M.; Yassien, E.E.; "Mitigation of Cisplatin-Induced Hepatotoxicity by Salvia officinalis: Attenuation of Oxidative Damage and Inflammation in Rats". Free Radic. Biol. Med., 222: 62-71, 2024.
[93] García-Muñoz, A.M.; Victoria-Montesinos, D.; Ballester, P.; Cerdá, B.; Zafrilla, P.; "A Descriptive Review of the Antioxidant Effects and Mechanisms of Action of Berberine and Silymarin". Molecules, 29 (19): 4576, 2024.
[94] Valková, V.; Ďúranová, H.; Bilčíková, J.; Habán, M.; "Milk Thistle (Silybum marianum): A Valuable Medicinal Plant with Several Therapeutic Purposes". J. Microbiol. Biotechnol. Food Sci., 9 (4): 836, 2020.
[95] Kidd, P.M.; "Glutathione: Systemic Protectant Against Oxidative and Free Radical Damage". Altern. Med. Rev., 2(3): 155-176, 1997.

[96] Leong, P.K.; Ko, K.M.; "Schisandrin B: A Double-Edged Sword in Nonalcoholic Fatty Liver Disease". Oxid. Med. Cell. Longev., 2016: 6171658, 2016.
[97] Vargas-Mendoza, N.; Madrigal-Santillán, E.; Morales-González, Á.; Esquivel-Soto, J.; Esquivel-Chirino, C.; y González-Vargas-Mendoza Rubio, M.G.; Gayosso-de-Lucio, J.A.; Morales-González, J.A.; "Hepatoprotective Effect of Silymarin". World J. Hepatol., 6 (3): 144, 2014.
[98] de Porras, V.R.; Figols, M.; Font, A.; Pardina, E.; "Curcumin as a Hepatoprotective Agent Against Chemotherapy-Induced Liver Injury". Life Sci., 332: 122119, 2023.
[99] Rahayuningsih, E.; Yanuarti, T.; "Effectiveness of Generation of Red Ginger and Mint Leaves to Reduce Hyperemisis Gravidarum in the 1st Trimester Pregnant Women". J. Keperawatan Komprehensif (Comprehensive Nursing Journal) 2023, 9 (SpecialEdition).
[100] Inchingolo, F.; Inchingolo, A.D.; Latini, G.; Trilli, I.; et al.; "The Role of Curcumin in Oral Health and Diseases: A Systematic Review". *Antioxidants*, *13* (6): 660, 2024.
[101] Nguyen, C.T.; Taw, M.B.; Wang, M.B.; "Integrative Care of the Patient With Head and Neck Cancer". *Laryngosc. Investig. Otolaryngol.*, *3* (5): 364-371, 2018.
[102] Tao, W.W.; Jiang, H.; Tao, X.M.; Jiang, P.; et al.; "Effects of Acupuncture, Tuina, Tai Chi, Qigong, and Traditional Chinese Medicine Five-Element Music Therapy on Symptom Management and Quality of Life for Cancer Patients: A Meta-Analysis". *J. Pain Symptom Manage.*, *51* (4): 728-747, 2016.
[103] Borges, J.Y.; "Mitigating the Opioid Epidemic: The Role of Cannabinoids in Chronic Pain Management—A Systematic Review and Meta-Analysis of Clinical Evidence and Mechanisms". *medRxiv* **2024**: 2024-07. (Assuming medRxiv is used as the "journal name" since it's a preprint server)
[104] Mendelson, S.D.; *Herbal Treatment of Anxiety: Clinical Studies in Western, Chinese and Ayurvedic Traditions*; CRC Press: Boca Raton, FL, USA, 2022.
[105] Malfliet, A.; Kregel, J.; Meeus, M.; Roussel, N.; et al.; "Blended-Learning Pain Neuroscience Education for People with Chronic Spinal Pain: Randomized Controlled Multicenter Trial". *Phys. Thera.*, *98* (5): 357-368, 2018.
[106] Herndon, C.M.; Nee, D.; Atayee, R.S.; Craig, D.S.; et al.; "ASHP Guidelines on the Pharmacist's Role in Palliative and Hospice Care". *Am. J. Health-Syst. Pharm.*, *73* (17): 1351-1367, 2016.
[107] Malviya, S.; Malviya, N.; Johariya, V.; Saxena, R.; et al.; "Medicinal Plants Having Anti-Cancer Activity". In *Medicinal Plants and Cancer Chemoprevention*; CRC Press: Boca Raton, FL, USA; 55-162, 2024.
[108] Serpell, M.; Ratcliffe, S.; Hovorka, J.; Schofield, M.; et al.; "A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of THC/CBD Spray in Peripheral Neuropathic Pain Treatment". *Eur. J. Pain*, *18* (7): 999-1012, 2014.
[109] Mikulska, P.; Malinowska, M.; Ignacyk, M.; Szustowski, P.; et al.; "Ashwagandha (Withania somnifera)—Current Research on the Health-Promoting Activities: A Narrative Review". *Pharmaceutics*, *15* (4): 1057, 2023.
[110] Chou, R.; Wagner, J.; Ahmed, A.Y.; Morasco, B.J.; et al.; *Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update*; Agency for Healthcare Research and Quality: Rockville, MD, USA, 2022.
[111] Yoon, S.W.; Choi, G.J.; Lee, O.H.; Yoon, I.J.; et al.; "Comparison of Propofol Monotherapy and Propofol Combination Therapy for Sedation During Gastrointestinal Endoscopy: A Systematic Review and Meta-Analysis". *Dig. Endosc.*, *30* (5): 580-591, 2018.
[112] Salve, J.; Pate, S.; Debnath, K.; Langade, D.; Langade, D.G.; "Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-Blind, Randomized, Placebo-Controlled Clinical Study". *Cureus*, *11* (12): e6466, 2019.
[113] Spinella, M.; "The Importance of Pharmacological Synergy in Psychoactive Herbal Medicines". *Altern. Med. Rev.*, *7* (2): 130-137, 2002.
[114] Shinjyo, N.; Waddell, G.; Green, J.; "Valerian Root in Treating Sleep Problems and Associated Disorders—A Systematic Review and Meta-Analysis". *J. Evid. Based Integr. Med.*, *25*: 2515690X20967323, 2020.
[115] Müller, C.P.; Schumann, G.; "Drugs as Instruments: A New Framework for Non-Addictive Psychoactive Drug Use". *Behav. Brain Sci.*, *34* (6): 293-310, 2011.
[116] Kaushal, V.; Chand, P.; Rupanagunta, G.P.; Joshi, R.; et al.; "Investigating the Therapeutic Potential of Medicinal Plants in

Managing Mental Health Disorders". In *Ethnopharmacology and OMICS Advances in Medicinal Plants Volume 2: Revealing the Secrets of Medicinal Plants*; Springer Nature Singapore: Singapore; 515-530, 2024.

[117] Zahiruddin, S.; Basist, P.; Parveen, A.; Parveen, R.; et al.; "Ashwagandha in Brain Disorders: A Review of Recent Developments". *J. Ethnopharmacol.*, *257*: 112876, 2020.

[118] Ross, S.M.; "Psychophytomedicine: An Overview of Clinical Efficacy and Phytopharmacology for Treatment of Depression, Anxiety and Insomnia". *Holist. Nurs. Pract.*, *28* (4): 275-280, 2014.

[119] Bannuru, R.R.; Osani, M.C.; Al-Eid, F.; Wang, C.; "Efficacy of Curcumin and Boswellia for Knee Osteoarthritis: Systematic Review and Meta-Analysis". In *Semin. Arthritis Rheum.*; WB Saunders, 48(3): 416-429, 2018.

[120] Liebelt, D.J.; Jordan, J.T.; Doherty, C.J.; "Only a Matter of Time: The Impact of Daily and Seasonal Rhythms on Phytochemicals". Phytochem. Rev., 18: 1409-1433, 2019.

[121] Busia, K.; Fundamentals of Herbal Medicine: Major Plant Families, Analytical Methods, Materia Medica; Xlibris Corporation, 2016.

[122] Salinas-Arellano, E.D.; Castro-Dionicio, I.Y.; Jeyaraj, J.G.; Mirtallo Ezzone, N.P.; Carcache de Blanco, E.J.; "Phytochemical Profiles and Biological Studies of Selected Botanical Dietary Supplements Used in the United States". In Progress in the Chemistry of Organic Natural Products 122: Botanical Dietary Supplements and Herbal Medicines; Springer Nature Switzerland: Chem.: 1-162, 2023.

[123] Durazzo, A.; Sorkin, B.C.; Lucarini, M.; Gusev, P.A.; Kuszak, A.J.; Crawford, C.; Boyd, C.; Deuster, P.A.; Saldanha, L.G.; Gurley, B.J.; Pehrsson, P.R.; "Analytical Challenges and Metrological Approaches to Ensuring Dietary Supplement Quality: International Perspectives". Front. Pharmacol., 12: 714434, 2022.

[124] Govindaraghavan, S.; Sucher, N.J.; "Quality Assessment of Medicinal Herbs and Their Extracts: Criteria and Prerequisites for Consistent Safety and Efficacy of Herbal Medicines". Epilepsy Behav., 52: 363-371, 2015.

[125] Budala, D.G.; Martu, M.A.; Maftei, G.A.; Diaconu-Popa, D.A.; Danila, V.; Luchian, I.; "The Role of Natural Compounds in Optimizing Contemporary Dental Treatment—Current Status and Future Trends". J. Funct. Biomater., 14 (5): 273, 2023.

[126] Rahimi, R.; Abdollahi, M.; "An Update on the Ability of St. John's Wort to Affect the Metabolism of Other Drugs". Expert Opin. Drug Metab. Toxicol., 8 (6): 691-708, 2012.

[127] Khatri, V.; Dey, P.K.; "Exploring the Dielectric Properties of Herbal Medicine and Modern Pharmaceuticals: An Integrative Review". Front. Pharmacol., 15: 1536397, 2025.

[128] Zhao, M.; Ma, J.; Li, M.; Zhang, Y.; Jiang, B.; Zhao, X.; Huai, C.; Shen, L.; Zhang, N.; He, L.; Qin, S.; "Cytochrome P450 Enzymes and Drug Metabolism in Humans". Int. J. Mol. Sci. 2021, 22 (23): 12808.

[129] Kober, M.; Pohl, K.; Efferth, T.; "Molecular Mechanisms Underlying St. John's Wort Drug Interactions". Curr. Drug Metab., 9 (10): 1027-1037, 2008.

[130] Izzo, A.A.; Hoon-Kim, S.; Radhakrishnan, R.; Williamson, E.M.; "A Critical Approach to Evaluating Clinical Efficacy, Adverse Events and Drug Interactions of Herbal Remedies". Phytother. Res., 30 (5): 691-700, 2016.

[131] Gonçalves, S.; Fernandes, L.; Caramelo, A.; Martins, M.; Rodrigues, T.; Matos, R.S.; "Soothing the Itch: The Role of Medicinal Plants in Alleviating Pruritus in Palliative Care". Plants, 13 (24): 3515, 2024.

[132] Sathvika, V.P.; Subhas, P.G.; Bhattacharjee, D.; Koppad, V.N.; Samrat, U.; Karibasappa, S.B.; Sagar, K.M.; "Review of Case Study Results: Assessing the Effectiveness of Curcumin, St. John's Wort, Valerian Root, Milk Thistle, and Ashwagandha in the Intervention for Obsessive-Compulsive Disorder". Drugs Drug Candidates, 3 (4): 838-859, 2024.

[133] Edo, G.I.; Ndudi, W.; Ali, A.; Yousif, E.; Zainulabdeen, K.; Onyibe, P.N.; Ekokotu, H.A.; Isoje, E.F.; Igbuku, U.A.; Essaghah, A.E.; Ahmed, D.S.; "An Updated Review on the Modifications, Recycling, Polymerization, and Applications of Polymethyl Methacrylate (PMMA)". J. Mater. Sci.: 1-44, 2024.

[134] Mohamed, S.H.; Yousif, E.; Hameed, A.S.; Ahmed, D.S.; Zainulabdeen, K.; Saleh, H.M.; Husain, A.A.; Bufaroosha, M.; "Morphology and Performance of PolyVinyl Chloride Thin Films Doped with Polyorganosilanes Against Photodegradation". Silicon, 15 (9): 4027-4038, 2023.

[135] Edo, G.I.; Ndudi, W.; Ali, A.B.; Yousif, E.; Zainulabdeen, K.; Onyibe, P.N.; Ekokotu, H.A.; Isoje, E.F.; Igbuku, U.A.; Essaghah, A.E.; Ahmed, D.S.; "Poly (Vinyl Chloride)(PVC): An Updated Review of Its Properties, Polymerization, Modification, Recycling, and Applications". J. Mater. Sci.: 1-44, 2024.

[136] Haddad, R.A.; Alsayed, R.; Ahmed, D.S.; Bufaroosha, M.; Salih, N.; Mohammed, S.A.; Yousif, E.; "Environmental Performance of Coordination Complexes as PVC Photostabilizers". Mater. Today Proc., 42: 2849-2852, 2021.

[137] Hassan, A.A.; Adil, H.; Alyasiri, T.; Alsayed, R.; Makia, R.; Kadhom, M.; Salman, H.; Yousif, E.; "Nickel Oxide Nanoparticles with Ginger Extract: An Environmentally Sustainable Method for Antibacterial Applications". Results Chem., 9: 101617, 2024.

[138] Sarris, J.; "Herbal Medicines in the Treatment of Psychiatric Disorders: 10-Year Updated Review". Phytother. Res., 32 (7): 1147-1162, 2018.

[139] Gobinath, T.; Ravichandran, S.; "Obsessive-Compulsive Disorder and Treatment with Effective Nature Supplements". In Nutrition and Obsessive-Compulsive Disorder; CRC Press: Boca Raton, FL, USA; 158-170, 2023.

[140] Feng, J.; Li, Z.; Tian, L.; Mu, P.; Hu, Y.; Xiong, F.; Ma, X.; "Efficacy and Safety of Curcuminoids Alone in Alleviating Pain and Dysfunction for Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". BMC Complement. Med. Ther., 22 (1): 276, 2022.

[141] Califf, R.M.; Peterson, E.D.; Gibbons, R.J.; Garson, A.; Brindis, R.G.; Beller, G.A.; Smith, S.C.; "Integrating Quality Into the Cycle of Therapeutic Development". J. Am. Coll. Cardiol., 40 (11): 1895-1901, 2002.